Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a bifunctional fusion protein designed to promote immune tolerance by inducing iTregs from Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells. The company also develops CUE-101, which is in phase 1b clinical trial to treat HPV+ recurrent metastatic, or head and neck squamous cell carcinoma in second line, and beyond patients as a monotherapy, as well as in phase 1b clinical trial for the treatment of head and neck squamous cell carcinoma as a first line, therapy in combination with standard of care KEYTRUDA; and CUE-102, which is in phase 1b clinical trial as a monotherapy in late line recurrent metastatic WT1+ colorectal, gastric, ovarian, and pancreatic cancer. It has collaboration agreements with LG Chem, Ltd. for the development of CUE-101 and CUE-102 Immuno-STATs; collaboration and option agreement with Ono Pharmaceutical Co., Ltd to development and commercialization rights for CUE-401; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
| Business Activity | PASS |
| Debt Ratio (0.04%) | PASS |
| Cash Ratio (0.29%) | PASS |
| Receivables Ratio (0.00%) | PASS |
| Revenue Ratio (0.00%) | PASS |
| Overall | PASS |
| Date | EPS Est. | Reported EPS | Surprise % |
|---|---|---|---|
| 2026-05-14 | -3.30 | -1.08 | +67.3% |
| 2026-03-16 | -2.70 | 0.30 | +111.1% |
| 2025-11-12 | -2.55 | -2.10 | +17.6% |
| 2025-08-12 | -3.90 | -2.70 | +30.8% |
| 2025-05-12 | -4.60 | -5.10 | -10.9% |
| 2025-03-31 | -4.35 | -3.84 | +11.7% |
| 2024-11-14 | -5.70 | -5.13 | +10.0% |
| 2024-08-14 | -8.40 | -6.00 | +28.6% |
| Period | Revenue | Net Income | EBITDA | Gross Profit | Op. Income | EPS |
|---|---|---|---|---|---|---|
| 2026-03-31 | $5.7M | -$5.2M | -$4.2M | — | -$5.4M | -1.08 |
| 2025-12-31 | $21.9M | $1.6M | $3.3M | — | $2.0M | 0.30 |
| 2025-09-30 | $2.1M | -$7.4M | -$6.8M | — | -$7.5M | -2.10 |
| 2025-06-30 | $3.0M | -$8.5M | -$7.6M | — | -$8.6M | -2.70 |
| 2025-03-31 | $421.0K | -$12.3M | -$11.2M | — | -$12.3M | -4.95 |
| 2024-12-31 | — | — | — | — | — | — |
| Date | Name | Role | Shares | Value |
|---|---|---|---|---|
| 2025-12-30 | SARRAF PASHA | Director | 323,857 | $99.7K |
| 2024-12-16 | PASSERI DANIEL R | Chief Executive Officer | 30,000 | $30.9K |
| Holder | Shares | Value | % Held |
|---|---|---|---|
| Bleichroeder LP | 227.3K | $4.9M | 0.1% |
| GC Wealth Management RIA, LLC | 154.4K | $3.3M | 0.0% |
| Vanguard Capital Management LLC | 81.9K | $1.8M | 0.0% |
| Lion Point Capital, LP | 73.4K | $1.6M | 0.0% |
| Geode Capital Management, LLC | 35.5K | $761.9K | 0.0% |
| Vanguard Fiduciary Trust Co | 18.1K | $389.0K | 0.0% |
| Robertson Stephens Wealth Management, LLC | 15.9K | $342.4K | 0.0% |
| Blackrock Inc. | 15.0K | $321.4K | 0.0% |
| Texas Capital Bank Wealth Management Services, Inc. | 13.2K | $284.4K | 0.0% |
| Angeles Wealth Management, LLC | 10.3K | $221.8K | 0.0% |
$72.9M
3.23
2.386
1
$27.5M
$3.4M
1.00
0.32
0.1%
29
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| 2026-05-14 | $-3.30 | $-1.08 | +67.3% |
| 2026-03-16 | $-2.70 | $0.30 | +111.1% |
| 2025-11-12 | $-2.55 | $-2.10 | +17.6% |
| 2025-08-12 | $-3.90 | $-2.70 | +30.8% |
| 2025-05-12 | $-4.60 | $-5.10 | -10.9% |
| 2025-03-31 | $-4.35 | $-3.84 | +11.7% |
| Shares | Cost | Profit to Target | R:R |
|---|---|---|---|
| To Consensus ($115.00, 1 analysts) | |||
| 10 | $229.70 | +$920.30 (401%) | 26.7R |
| 50 | $1,148.50 | +$4,601.50 (401%) | 26.7R |
| 100 | $2,297.00 | +$9,203.00 (401%) | 26.7R |
- High beta (2.39) — amplifies market moves by 2.39x
A single score combining all analytical layers below. A is strongest, D is weakest.
How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.
Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.
What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?
Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.
Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.
These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.
| Ticker | Correlation |
|---|---|
| LWLG | 0.272 |
| FIVN | 0.250 |
| ARKG | 0.233 |
| FUBO | 0.232 |
| 0981.HK | 0.231 |
| Ticker | Correlation |
|---|---|
| PLBL | -0.159 |
| IPG.KW | -0.140 |
| 1605.T | -0.133 |
| SOKOUK.KW | -0.131 |
| BAES.L | -0.117 |
Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.
After this company beats earnings, does the price keep going up? Drift tracks post-earnings momentum.
How does this ticker's recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.